Oncurious NV has announced the appointment of Prof Dr Peter Carmeliet as its Chief Scientific Strategy Advisor. Oncurious is a new oncology company and a joint venture between ThromboGenics NV and VIB, a leading life sciences institute in Flanders (Belgium).
Since 15 years Prof Carmeliet (VIB Vesalius Research Center, KU Leuven) has focused his research interests on unravelling the molecular basis of neuro-vascular biological processes and diseases, and translating these genetic insights into therapeutic concepts – with the ultimate aspiration to develop novel treatments.
Research conducted by Prof Carmeliet’s team at VIB/KU Leuven, in collaboration with Prof Rakesh Jain from the Massachusetts General Hospital at Harvard (Boston), generated the first pre-clinical data on the use of human monoclonal antibodies against placental growth factor (PlGF) in the treatment of medulloblastoma. Based on the positive results, TB-403 will be now further developed by Oncurious for the treatment of pediatric tumors.
Prof Dr Peter Carmeliet comments: “I am pleased with this opportunity to support the translation of pre-clinical research conducted at VIB/KU Leuven and other world leading institutes into potential novel cancer treatments. Working with Oncurious NV gives me the occasion to remain very closely involved in the process of developing a drug for clinical use.”
Dr Patrik De Haes, CEO of ThromboGenics NV and Executive Chairman of Oncurious NV: We are delighted that Prof Carmeliet has accepted the role of Chief Scientific Strategy Advisor with Oncurious. Professor Carmeliet is a globally renowned leader in the field of oncology research and its underlying biological processes. His scientific insights, research and in-depth expertise will be very valuable as the Oncurious team progresses its current clinical development of TB-403 for the treatment of pediatric brain tumors, I am confident that his insights will, in time, allow Oncurious to build an oncology pipeline and become an international leader in developing novel cancer therapies.”